GO Therapeutics

Website: GO Therapeutics


GO Therapeutics identifies sites of O-linked glycosylation on a wide range of proteins targets. The accessibility of these O-glycans at the plasma membrane is used to develop novel “hybrid” epitopes that are part protein and O-glycan structure. These structures are exclusive to the tumor, and not resident on normal healthy cells, making them ideal targets for potent immune-based cell therapies and antibody-drug-conjugates.

Cambridge MA
United States